ProCE Banner Activity

Individualizing ART Management in 2023 and Beyond

Video

Hear expert faculty address major factors driving ART individualization in 2023—including the latest data on ART-related weight gain and cardiometabolic complications—and how future ART regimens may offer additional options.

Released: October 04, 2023

Share

Faculty

Brenda E. Crabtree Ramírez

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Tristan J. Barber

Tristan J. Barber, MA, MD, FRCP

Consultant in HIV Medicine
Royal Free London NHS Foundation Trust
Honorary Associate Professor
Institute for Global Health
University College London
London, United Kingdom

Roger Bedimo

Roger Bedimo, MD, MS, FACP

Professor of Medicine
Interim Director, Office of Global Health, UT Southwestern Medical Center
Chief, Infectious Diseases Section, VA North Texas Health Care System
Dallas, Texas

Janine Trevillyan

Janine Trevillyan, MBBS, PhD, FRACP

Associate Professor
Department of Infectious Diseases
Peter Doherty Institute of Infection and Immunity at University of Melbourne
Head, Clinical Virology and HIV Services
Deputy Director
Department of Infectious Diseases
Austin Health
Melbourne, Victoria

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through an Independent Medical Education grant from Merck Sharp & Dohme LLC, Rahway, NJ, USA.

Merck Sharp & Dohme LLC, Rahway, NJ, USA

Disclosure

Primary Author

Tristan J. Barber, MA, MD, FRCP

Consultant in HIV Medicine
Royal Free London NHS Foundation Trust
Honorary Associate Professor
Institute for Global Health
University College London
London, United Kingdom

Tristan J. Barber, MA, MD, FRCP: consultant/advisor/speaker: Gilead, Janssen, Merck Sharpe & Dohme, ViiV/GlaxoSmithKline.

Roger Bedimo, MD, MS, FACP

Professor of Medicine
Interim Director, Office of Global Health, UT Southwestern Medical Center
Chief, Infectious Diseases Section, VA North Texas Health Care System
Dallas, Texas

Roger Bedimo, MS, MS, FACP: consultant/advisor/speaker: Gilead, Janssen, Merck, Sanofi, Theratechnologies, ViiV.

Janine Trevillyan, MBBS, PhD, FRACP

Associate Professor
Department of Infectious Diseases
Peter Doherty Institute of Infection and Immunity at University of Melbourne
Head, Clinical Virology and HIV Services
Deputy Director
Department of Infectious Diseases
Austin Health
Melbourne, Victoria

Janine Trevillyan, MBBS, PhD, FRACP: consultant/advisor/speaker: Gilead Health Sciences.

Program Director

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Brenda E. Crabtree Ramírez, MD: researcher: Janssen, MSD, ViiV.